Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Imaging, Diagnosis, Prognosis

Computer-Assisted Analysis of Biopsy Specimen Microvessels Predicts the Outcome of Esophageal Cancers Treated with Chemoradiotherapy

Shi-chuan Zhang, Shuichi Hironaka, Atsushi Ohtsu, Shigeaki Yoshida, Takahiro Hasebe, Masashi Fukayama and Atsushi Ochiai
Shi-chuan Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuichi Hironaka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Ohtsu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeaki Yoshida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takahiro Hasebe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masashi Fukayama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Ochiai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-05-1982 Published March 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: A computer-assisted microvessel analysis system was developed to evaluate correlations between the architecture of biopsy specimen microvessels and the outcome for patients with esophageal cancer treated with chemoradiotherapy.

Experimental Design: Biopsy specimens from 51 patients with esophageal cancer (T2-3, any N, M0) treated with chemoradiotherapy were immunostained with an anti-CD31 antibody and quantified using computerized image analysis. We evaluated the association of several microvessel factors with overall survival, including the ratio of total microvessel perimeter to total tumor area (TP/TA), the tumor hypoxic ratio, and the ratio of total microvessel number to total tumor area (TN/TA). Results from traditional manual microvessel density (MVD) hotspot count and computerized hotspot count were compared and the relation between hotspot MVD count and survival rate was evaluated.

Results: The median follow-up time was 32 months. Both univariate and multivariate analyses revealed that computer-counted hotspot MVD and TN/TA and TP/TA ratios correlated significantly with the outcome of chemoradiotherapy. Kaplan-Meier survival curves showed that patients with high computer-counted hotspot MVDs and high TN/TA and TP/TA ratios had better overall survival rate than patients with low MVDs or ratios (P = 0.025, 0.008, and 0.031, respectively). Combining computer-counted MVD or TN/TA ratio with TP/TA ratio proved more predictive than any single factor. Two researcher-counted hotspot MVDs had no significant relation with outcome.

Conclusion: Computer-assisted tumor microvessel analysis is a powerful tool in predicting the outcome for patients with esophageal cancer treated with chemoradiotherapy because intraobserver and interobserver variability is minimized.

  • esophageal
  • carcinoma
  • chemoradiotherapy
  • microvessel
  • prognosis

Esophageal cancer is a common malignancy that causes ∼10,000 deaths each year in Japan (1) and >300,000 deaths annually worldwide (2). Surgery with or without preoperative chemoradiotherapy is generally done for resectable cases and chemoradiotherapy is used for unresectable cases or resectable cases where patients do not wish to have surgery. In recent years, chemoradiotherapy is increasingly being reported as a curative treatment modality for clinically resectable cases, which does not compromise disease control. In the Radiation Therapy Oncology Group 85-01 randomized trial, definitive chemoradiotherapy using 5-fluororuracil, cis-diammine-dichloroplatinum (cisplatin), and concurrent radiation (50 Gy) has achieved a 26% 5-year survival (3), similar to surgery alone (4, 5). Stahl et al. (6) reported a randomized trial comparing chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma. Chemoradiotherapy resulted in equivalent survival compared with chemoradiotherapy followed by surgery.

Because chemoradiotherapy can achieve similar survival rates to surgery or surgery combined with chemoradiotherapy, patient characteristics and tumor histologic features that favor chemoradiotherapy should be carefully assessed before choosing treatment. However, the factors that can predict the response to treatment of esophageal cancer remain uncertain. In our studies, we reported that hotspot microvessel density (MVD) in biopsy specimen is of strong prognostic significance for patients with laryngeal squamous cell cancers and with hypopharyngeal cancers treated with radiation (7, 8). The ratio of total microvessel perimeter (TP) to total tumor area (TA) of biopsy specimens, the ratio of total microvessel number (TN) to TA, and the tumor hypoxic ratio calculated from microvessel distributions in biopsy specimens have been further proved to be good prognostic factors for patients with early stages of laryngeal carcinoma treated with radiation (9). In the present study, microvessel factors, including hotspot MVD and TP/TA, TN/TA, and hypoxic ratios, in biopsy specimens from 51 patients with esophageal cancer treated with chemoradiotherapy were analyzed, and the relations between these factors and overall survival were assessed. All factors including tumor hotspot MVD counts were analyzed using a computer-assisted image analysis system, with the aim of minimizing intraobserver and interobserver variation in microvessel counting and analysis.

Materials and Methods

Patients. A total of 348 patients with esophageal cancers were diagnosed and treated at the National Cancer Center Hospital East between 1992 and 1999. Surgery was done as the main treatment for 139 patients, and 209 received definitive chemoradiotherapy. Among the 209 patients, 51 met the following criteria to be included in this study: (a) the tumor was histologically diagnosed as squamous cell carcinoma; (b) patient age was ≤75 years; (c) sufficient biopsy specimens (tumor area >0.6 mm2, which is about thrice of ×400 magnification field) were available before treatment; (d) performance status on the Eastern Cooperative Oncology Group scale ≤2; and (e) stage T2-3, any N, M0 on the International Union against Cancer tumor-node-metastasis classification. The patients' characteristics are listed in Table 1 .

View this table:
  • View inline
  • View popup
Table 1.

Patient characteristics

Treatment protocol. Chemotherapy consisted of continuous infusion of 5-fluorouracil (400 mg/m2/d, on days 1-5 and 8-12) and a weekly infusion of cisplatin (40 mg/m2, days 1 and 8). Concurrent radiotherapy was given at 2 Gy/d for 5 d/wk with a 2-week break after a dose of 30 Gy, and restarted on day 36 along with the same schedule of chemotherapy as before. The total radiation dose was 60 Gy. After concurrent chemoradiotherapy, two additional courses of chemotherapy (5-fluorouracil, 800 mg/m2/d, on days 1-5 and 29-33; cisplatin, 80 mg/m2, on days 1 and 29) were basically administered if patients responded to treatment without serious side effect. Further additional courses were optional although they were limited to a total of four courses.

Definition of tumor response. The first evaluation was done ∼1 month after treatment. Patients then received computed tomography scanning and esophagoscopy every 2 or 3 months during the first year and every 6 months thereafter. Tumor recurrences were all proved histologically by biopsy.

Response at the primary site was evaluated by endoscopic examination. The criteria for evaluation were as follows: complete remission was defined as disappearance of tumor lesion and ulceration for ≧4 weeks with negative biopsy results; partial remission was determined when primary tumor was observed on esophagography as being reduced in area by ≧50%. Responses of metastatic lymph nodes were assessed by computed tomography scanning according to the WHO criteria for measurable disease.

Immunohistochemical staining of blood microvessels and computer-assisted image analysis. All biopsy specimens were taken at the time of diagnosis. Immunohistochemical staining of blood microvessels was done with the standard avidin-biotin complex technique using diaminobenzidine as a chromogen and hematoxylin as counterstain. Antigen was retrieved by treating with 0.05% pepsin in 0.01 N HCl for 5 minutes at room temperature. A mouse antibody for CD31 was used as primary antibody (4°C, overnight, 1:50 dilution; DAKO, Glostrup, Denmark). After washing, sections were incubated with an avidin-biotin complex reagent (DAKO). Color reactions were developed for 5 minutes in diaminobenzidine-Tris buffer (pH 7.6) containing 0.3% hydrogen peroxide.

Digitized images of immunohistochemically stained sections of whole specimen at ×100 magnification (10× objective and 10× ocular) were obtained using a KS 300 image analysis system (capture resolution 768 × 580, Karl Zeiss Vision K.K., Jena, Germany). Vessels with lumens located around or inside tumor nest were traced by one of the authors (H.S.). The process of image analysis has been described elsewhere (9). Briefly, traced microvessels and the outline of the total specimen were converted to binary images and TN, TP, and TA were calculated. Data were recorded as TN/TA, TP/TA, and TP/TA ratios. As the oxygen diffusion distance from blood vessels is ∼150 μm (10), the hypoxic ratio was calculated as the ratio of tumor area >150 μm from blood vessels to the TA (Fig. 1A ).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

A, image analysis of microvessels. I, the lumen of each microvessel was traced by an observer and counted by the computer. The TP was then calculated using the computer. II, the tumor region was outlined by the observer and the tumor area was calculated using the computer. III, the area of the tumor located >150 μm from the nearest vessel was calculated by the computer (yellow area) and then hypoxia ratio was calculated. B, microvessel hotspot counted by computer. I, microvessels were labeled by an observer. Bar, 100 μm. II, labeled vessels were converted to binary images. III, the scanning circle is 500 μm in diameter and 0.196 mm2 in area, which equals the area of a ×400 power field. The overlay of two neighboring circles is 375 μm. IV, the binary image was scanned. V, a schematic image of microvessel distribution derived from computer analysis. VI, areas with the highest microvessel number were identified as microvessel hotspots.

Two of the authors (Z.S. and H.S.) counted hotspot microvessel numbers independently without knowledge of patient outcomes. The immunohistochemically stained specimens were first scanned at low magnification (×10-×100); three high-magnification (×400) fields with plentiful vascular tumor areas were then selected and counted as hotspots. The mean number of vessels from three fields was recorded as the hotspot MVD.

As an alternative for manual counting, a computer-assisted method was used to identify hotspot and count vessels in specimens. The previously traced vessels were converted to binary images and were scanned consecutively. The scanning circle was 500 μm in diameter and 0.196 mm2 in area, which was the same as a ×400 magnification field. Microvessels within each circle were counted by computer. The overlay of adjacent circles in both the X and Y axes was set arbitrarily at 375 μm (three fourths of the diameter). The mean number of MVDs in the three circles containing the highest MVD count was recorded as the hotspot MVD of the corresponding specimen (Fig. 1B).

Statistical analysis. Correlations between different factors were assessed using Pearson's correlation coefficient. A Cox proportional hazard analysis was used to evaluate clinicopathologic and microvessel factors in the prediction of treatment outcome. Survival curves were generated using the Kaplan-Meier method and statistical differences between curves were calculated using the log-rank test. For evaluation of continuous variables in survival analysis, patients were divided into two groups based on an optimal cutoff derived from receiver operating characteristic analysis. GraphPad Prism software (GraphPad Software, San Diego, CA) was used for receiver operating characteristic analysis and Statistica (StatSoft, Tulsa, OK) was used for all other analysis.

Results

Treatment outcome. All 51 patients completed the concurrent chemoradiotherapy with a total radiation dose of 60 Gy. Seven patients (14%) received one additional course of chemotherapy, and 25 patients (49%), 2 patients (4%), and 2 patients (4%) received an additional two, three, and four courses, respectively. The median patient follow-up time was 32 months (range, 5.9-121.5 months). Thirty-nine patients (76%) achieved clinical complete remission and 12 patients (24%) achieved partial remission at primary site. Among the 39 with clinical complete remission at primary site, 12 patients developed recurrence in the primary area, 3 in a distant area (a different site in esophagus), and 4 had distant metastases during follow-up (3 in the liver and 1 in the lung). Up to January 1, 2005, 23 patients had died of esophageal cancer, 8 patients died of other disease or accidents, and the other 20 cases were alive at the last follow-up time point.

Image analysis of microvessels in biopsy specimens. Areas of inflammation, sclerotic tumor, and adjacent benign tissue were identified and excluded by observer when calculating the TA, which ranged from 0.99 to 3.37 mm2, with a median of 1.92 mm2. The TN varied from 3 to 204, with a median of 100. The TP ranged from 0.35 to 41.26 mm, with a median of 11.81 mm. Tumor hypoxic ratio ranged from 0.11% to 78.63%, with a median of 8.34%.

Comparison of manual MVD counting and computer-assisted MVD counting. The results of two manual MVD counts and the computer-assisted counts are shown in Table 2 .

View this table:
  • View inline
  • View popup
Table 2.

Correlation between different MVDs

Although hotspot MVD counts for a given patient varied between different observers and the computer, analysis showed that they were correlated linearly (Table 2).

Receiver operating characteristic analysis. To evaluate the ability for the prediction of survival, we evaluated the accuracy of prediction of death of esophageal cancer at 2 years for each microvessel factor. This interval of 2 years was selected because most of the complete cases happened in this interval (19 in 23 cases) and only three patients (all of whom died of other diseases and were excluded from the receiver operating characteristic analysis) censored before the end of 2 years. The predictive power was estimated by calculating the area under receiver operating characteristic curves (11, 12). All factors, including TN/TA, TP/TA, and hypoxic ratios and observer-counted and computer-derived hotspot MVDs, were found to be predictors of 2-year survival (Table 3 ); the observer-counted MVD showed the weakest power in predicting death 2 years after treatment.

View this table:
  • View inline
  • View popup
Table 3.

Receiver operating characteristic curve analysis

Univariate analysis of survival. Univariate Cox proportional hazard analysis was done to evaluate the relation between clinicopathologic factors and overall survival. The result is presented in Table 4 . No clinicopathologic factor correlated with overall survival.

View this table:
  • View inline
  • View popup
Table 4.

Univariate Cox proportional hazard analysis of relations between clinical and pathologic characteristics and overall survival

From the receiver operating characteristic curves, the optimal cutoffs for varied microvessel factors were determined to stratify patients into two groups, and univariate Cox proportional analysis revealed that patients with low TN/TA (P = 0.023) or low TP/TA (P = 0.037) had a higher risk of dying of esophageal cancer after chemoradiotherapy (Table 5 ). Patients with a low ratio of tumor hypoxic area tended to survive longer after treatment but this was not statistically significant (P = 0.329). The hotspot MVDs counted by the two observers had no relation with overall survival (P = 0.203 and 0.119, respectively) whereas hotspot MVDs counted by the computer showed a significant association with survival (P = 0.036).

View this table:
  • View inline
  • View popup
Table 5.

Univariate Cox proportional hazard analysis of relations between microvessel characteristic and overall survival

Multivariate analysis for survival. In the multivariate Cox proportional hazard analysis, computer-derived hotspot MVD counts and the TN/TA and TP/TA ratios were analyzed combined with T and N stage, which showed the highest significance among clinicopathologic factors by univariate analysis. All three microvessel factors proved to be independent predictors for overall survival (P = 0.019 for hotspot MVD, P = 0.018 for TN/TA, and P = 0.044 for TP/TA; Table 6 ).

View this table:
  • View inline
  • View popup
Table 6.

Multivariate Cox proportional hazard analysis of relations between microvessel characteristic and overall survival

Kaplan-Meier survival analysis.Figure 2 shows the survival curves generated using the Kaplan-Meier method. Patients with high MVD and high TN/TA and TP/TA ratios had 5-year survival rates of 73%, 79%, and 73%, respectively, whereas the group of patients with low such factors had 5-year survival rates of 46%, 45%, and 41%, respectively. Log-rank test showed that these differences were statistically significant (P = 0.025 for hotspot MVD, P = 0.008 for TN/TA, P = 0.031 for TP/TA).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Kaplan-Meier overall survival curves for patients with T2-3 M0 esophageal cancer treated with chemoradiotherapy.

Because hotspot MVD count and the TN/TA and TP/TA ratios all proved to be predictive factors for the outcome of patients treated with chemoradiotherapy, we investigated whether combinations of these factors would provide more powerful and more precise predictors. Hotspot MVD showed a strongly positive correlation with TN/TA (Pearson test, r = 0.843, P < 0.000001) whereas TP/TA was independent of hotspot MVD (r = 0.023) and was relatively weakly correlated with TN/TA (r = 0.318, P = 0.022). We therefore selected the combinations of MVD and TP/TA, TN/TA and TP/TA ratios as new factors and investigated if they could predict survival of patients. The high hotspot MVD plus high TP/TA group included eight patients and the high TN/TA plus high TP/TA included 11 patients (including all the eight in the high MVD plus high TP/TA group). Surprisingly, none of the patients with both high MVD and high TP/TA ratio died of esophageal cancer during follow-up and only one patient died of esophageal cancer in the high TN/TA plus high TP/TA group. The Kaplan-Meier survival curve of the high TN/TA plus high TP/TA group was presented in Fig. 3 .

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Kaplan-Meier overall survival curves for patients with high TN/TA and high TP/TA.

Discussion

We previously reported that hotspot MVD and the TN/TA, TP/TA, and hypoxic ratios in biopsy specimen are prognostic factors for laryngeal cancer patients treated by radiotherapy (9). Here we found that, for patients with T2-3 esophageal cancers, hotspot MVD, TN/TA, and TP/TA were favorable predictors for overall survival. The combinations of hotspot MVD with TP/TA, or TN/TA with TP/TA, may provide more powerful predictors for predicting the outcome of such patients scheduled to undergo chemoradiotherapy.

It is likely that a low density of microvessels will lead to a decrease in oxygen transport and drug delivery into local tumor environments. Bhattacharya et al. (13) investigated avascular regions of human head and neck cancer xenografts and found that cells in these areas were hypoxic and chemotherapy resistant. Hypoxia-related factors, such as hypoxia-induced factor 1α and carbonic anhydrase IX, and hypoxic area imaging by pimonidazole or misonidazole binding have been discussed as prognostic factors for radiotherapy of cancers (14–17). Although there are substantial data implying that poorly vascularized tumors are resistant to chemotherapy and/or radiotherapy, no definitive conclusion has been drawn at present on the clinical usefulness of MVD as a marker for prognosis. There are some studies that did not show a relationship between MVD and survival (18, 19) and a reverse relationship between MVD and survival has been reported by some groups (20, 21).

These contradictory conclusions might be explained by the difficulty in evaluating MVD accurately. Manual hotspot MVD counting has been the predominant method for analysis. The observer first scans a section at low magnification (×10-×100). High angiogenesis areas can be recognized as hotspots and a higher magnification (×200-×400) is then selected to count the number of microvessels in these areas (22). All procedures, including screening hotspot area and counting vessels, are done subjectively and intraobserver or interobserver variability is almost inevitable. Our study presents one resolution of this problem. Because pathologic section is converted into digitized image, the observer only needs to trace the outlines of the microvessels and the following work is all accomplished by the computer with minimum variability and perfect reproducibility. When two observers counted the microvessels of the same patients in our study using the manual hotspot counting method, the results differed and both failed to predict the survival of patients.

Using a computerized system to evaluate tumor microvessels has been reported by some groups (23–26). The present method has two novel features. The first is observer intervention in microvessel tracing. Although completely automated analysis will undoubtedly be developed, the nonspecific staining and the varying threshold for positive endothelial staining are likely to comprise this. Manual tracing ensures the accuracy of microvessel recognition and therefore maintains a high specificity of this analysis. The second feature is the use of full section scanning to determine microvessel hotspots, which provides the most objective information on microvessel distribution within any biopsy sample.

The tumor hypoxic ratio counted by computer has been shown as a predictor for radiosensitivity (9). In the present study, there was a tendency for a low hypoxic ratio to show good patient prognosis, but this was not statistically significant. The predictive power of the hypoxic ratio for the outcome of chemoradiotherapy thus needs further investigation.

A surprising finding in our study is that in the group of patients with both high hotspot MVD and high TP/TA ratios, none died of esophageal cancer, and in the group with high TN/TA and TP/TA ratios, only one patient died of esophageal cancer during follow-up. Six of eight patients (75%) in the high hotspot MVD plus high TP/TA ratio group and 8 of 11 patients (73%) in the high TN/TA plus high TP/TA ratio group survived longer than 3 years, compared with the average level of 45% (23 of 51) for all patients. These data suggested that well-vascularized tumor may be more sensitive to chemoradiotherapy.

The subjects of this study were patients who received definitive chemoradiotherapy. Because induction chemoradiotherapy before surgery is one of the most adopted multimodal treatments for esophageal cancer, whether the computer-assisted microvessel analysis is useful in predicting the outcome in these patients remains to be determined. After induction chemoradiotherapy, only 15% to 56% of patients achieved pathologic complete remission (27, 28). This method may be extremely helpful for treatment selection in residual disease after induction chemoradiotherapy. Similarly, the usefulness of this method in assessing treatment advantage of postoperative chemoradiotherapy is also an interesting topic needing further investigation.

Esophageal adenocarcinomas were not included in this study because most esophageal cancers in Japan (>90%) histologically are squamous cell carcinoma (29). However, in western countries, adenocarcinomas account for >60% of all esophageal cancers (5, 30). An independent study is needed to investigate whether microvessel analysis is suitable for adenocarcinoma when this method is expected to be used in these countries.

High MVD was reported to correlate with distant metastasis and short survival in solid tumors (31, 32). It should be noted that surgery was the main treatment modality in most of these prognosis analysis studies. For esophageal cancer, if it is proved that patients with a high MVD have short survival after surgery, chemoradiotherapy should then be more strongly recommended for these patients.

In conclusion, using a computer-assisted image analysis system for biopsy specimens, we found that hotspot MVD and the TN/TA and TP/TA ratios were powerful predictors for the outcome of patients with esophageal cancer treated with chemoradiotherapy. Compared with manual microvessel counting, this computer-assisted method produced lower variability and higher reproducibility for the evaluation of tumor vasculature.

Footnotes

  • Grant support: Grant-in-Aid for Cancer Research and Grant-in-Aid for the 3rd Term Comprehensive 10-Year-Strategy for Cancer Control from the Ministry of Health and Welfare of Japan.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted January 5, 2006.
    • Received September 9, 2005.
    • Revision received November 29, 2005.

References

  1. ↵
    Fujita H. Present status of esophageal cancer and its treatment in Japan. Ann Thorac Cardiovasc Surg 2004;10:135–9.
    OpenUrlPubMed
  2. ↵
    Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:4–66.
    OpenUrlCrossRef
  3. ↵
    Cooper JS, Guo MD, Herskovic A, et al. for the Radiation Therapy Oncology Group. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281:1623–7.
    OpenUrlCrossRefPubMed
  4. ↵
    Mullrt JM, Erasmi H, Stelzner M, et al. Surgical therapy of osesophageal carcinoma. Br J Surg 1990;77:845–57.
    OpenUrlPubMed
  5. ↵
    Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without pre-operative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002;359:1727–33.
    OpenUrlCrossRefPubMed
  6. ↵
    Stahl M, Stuschke M, Lehmann N, Meyer HJ. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310–7.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Kamijo T, Yokose T, Hasebe T, Yonou H, et al. Potential role of microvessel density in predicting radiosensitivity of T1 and T2 stage laryngeal squamous cell carcinoma treated with radiotherapy. Clin Cancer Res 2000;6:3159–65.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Zhang SC, Miyamoto S, Kamijo T, et al. Intratumor microvessel density in biopsy specimens predicts local response of hypopharyngeal cancer to radiotherapy. Jpn J Clin Oncol 2003;33:613–9.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Kamijo T, Yokose T, Hasebe T, et al. Image analysis of microvessel surface area predicts radiosensitivity in early-stage laryngeal carcinoma treated with radiotherapy. Clin Cancer Res 2001;7:2809–14.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539–49.
    OpenUrlCrossRefPubMed
  11. ↵
    Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002;106:319–24.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411–8.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Bhattacharya A, Toth K, Mazurchuk R, et al. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res 2004;10:8005–17.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Hutchison GJ, Valentine HR, Loncaster JA, et al. Hypoxia inducible factor 1α expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004;10:8405–12.
    OpenUrlAbstract/FREE Full Text
  15. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7:3399–403.
    OpenUrlAbstract/FREE Full Text
  16. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066–74.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253–60.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Haugen H, Magnusson B, Svensson M, et al. Preradiotherapy hemoglobin level but not microvessel density predicts locoregional control and survival in laryngeal cancer treated with primary radical radiotherapy. Clin Cancer Res 2004;10:7941–9.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Foote RL, Weidner N, Harris J, et al. Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505. Int J Radiat Oncol Biol Phys 2005;61:745–53.
    OpenUrlCrossRefPubMed
  20. ↵
    Cooper RA, Wilks DP, Logue JP, et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 1998;4:2795–800.
    OpenUrlAbstract
  21. ↵
    Aebersold DM, Beer KT, Laissue J, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys 2000;48:17–25.
    OpenUrlCrossRefPubMed
  22. ↵
    Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.
    OpenUrlCrossRefPubMed
  23. ↵
    Barbareschi M, Weidner N, Gasparini G, et al. Microvessel density quantification in breast carcinomas. Appl Immunohistochem 1995;3:75–84.
  24. Fox SB, Leek RD, Weekes MP, et al. Quantification and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count and computer image analysis. J Pathol 1995;177:275–83.
    OpenUrlCrossRefPubMed
  25. Canete A, Navarro S, Bermudez J, et al. Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J Clin Oncol 2000;18:27–34.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Chantrain CF, Declerck YA, Groshen S, et al. Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. J Histochem Cytochem 2003;51:151–8.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Laterza E, de' Manzoni G, Tedesco P, et al. Induction chemo-radiotherapy for squamous cell carcinoma of the thoracic esophagus: long-term results of a phase II study. Ann Surg Oncol 1999;6:777–84.
    OpenUrlCrossRefPubMed
  28. ↵
    Raoul JL, Le Prise E, Meunier B, et al. Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. Int J Radiat Oncol Biol Phys 1998;42:29–34.
    OpenUrlCrossRefPubMed
  29. ↵
    Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225–32.
    OpenUrlCrossRefPubMed
  30. ↵
    Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049–53.
    OpenUrlCrossRefPubMed
  31. ↵
    Hansen S, Grabau DA, Sorensen FB, et al. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 2000;6:139–46.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89:881–6.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 12 (6)
March 2006
Volume 12, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Computer-Assisted Analysis of Biopsy Specimen Microvessels Predicts the Outcome of Esophageal Cancers Treated with Chemoradiotherapy
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Computer-Assisted Analysis of Biopsy Specimen Microvessels Predicts the Outcome of Esophageal Cancers Treated with Chemoradiotherapy
Shi-chuan Zhang, Shuichi Hironaka, Atsushi Ohtsu, Shigeaki Yoshida, Takahiro Hasebe, Masashi Fukayama and Atsushi Ochiai
Clin Cancer Res March 15 2006 (12) (6) 1735-1742; DOI: 10.1158/1078-0432.CCR-05-1982

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Computer-Assisted Analysis of Biopsy Specimen Microvessels Predicts the Outcome of Esophageal Cancers Treated with Chemoradiotherapy
Shi-chuan Zhang, Shuichi Hironaka, Atsushi Ohtsu, Shigeaki Yoshida, Takahiro Hasebe, Masashi Fukayama and Atsushi Ochiai
Clin Cancer Res March 15 2006 (12) (6) 1735-1742; DOI: 10.1158/1078-0432.CCR-05-1982
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • TP53 in Breast Cancer
  • FDOPA PET Survival Predictions for Glioma
  • In vivo Fluorescence Lifetime Imaging for Monitoring the Cancer Treatment
Show more Imaging, Diagnosis, Prognosis
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement